Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 15/20 | 0.52 |
| ▸ | ERBB2 | P04626 | 6/20 | 0.52 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.48 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.47 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.47 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22590150 | 0.91 | EGFR (0.54) | EGFRERBB2ENPP1 | |
| SCHEMBL3133723 | 0.89 | PIK3CD (0.56) | EGFRERBB2PDE10A | |
| SCHEMBL2457829 | 0.89 | PIK3CD (0.56) | EGFRERBB2PDE10A | |
| SCHEMBL3134760 | 0.89 | PIK3CD (0.56) | EGFRERBB2PDE10A | |
| SCHEMBL4087511 | 0.89 | EGFR (0.56) | EGFRERBB2ENPP1 | |
| SCHEMBL3129523 | 0.89 | EGFR (0.56) | EGFRERBB2ENPP1 | |
| SCHEMBL5433323 | 0.85 | ENPP1 (0.52) | EGFRERBB2ENPP1PDE3A | |
| SCHEMBL5438862 | 0.85 | ENPP1 (0.52) | EGFRERBB2ENPP1PDE3A | |
| SCHEMBL29834791 | 0.82 | PIK3CD (0.62) | EGFRERBB2PDE10A | |
| SCHEMBL29834734 | 0.82 | PIK3CD (0.62) | EGFRERBB2PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090312343-A1 | QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS | HENNEQUIN LAURENT FRANCOIS AND | 2009-12-17 | — | — | US | disclosed |
| US-7569577-B2 | Quinazoline derivatives as tyrosine kinase inhibitors | ASTRAZENECA AB (SE) | 2009-08-04 | — | — | US | disclosed |
| EP-1667991-B1 | QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2008-05-14 | — | — | EP | disclosed |
| US-20070043009-A1 | Quinazoline derivatives as tyrosine kinase inhibitors | ASTRAZENECA AB (SE) | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312343-A1 | QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS | ERBB2, ABL1, EGFR | EGFR 3/4885ERBB2 1/4885PDE10A 3197/4885 |
| US-20070043009-A1 | Quinazoline derivatives as tyrosine kinase inhibitors | ERBB2, ABL1, EGFR | EGFR 3/4885ERBB2 1/4885PDE10A 3221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.